Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | PKLR | P30613 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997381 | 0.92 | HTR6 (0.40) | HTR6PKMPKLRSMN1; SMN2HTR2C | |
| SCHEMBL1998909 | 0.87 | HTR6 (0.38) | HTR6PKMPKLRHTR2C | |
| SCHEMBL1996682 | 0.85 | PKM (0.40) | HTR6PKMPKLRHTTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1998089 | 0.77 | HTR6 (0.39) | HTR6PKMPKLRHTTSMN1; SMN2 | |
| SCHEMBL1994437 | 0.74 | HTR6 (0.46) | HTR6HTTNPSR1HTR2C | |
| SCHEMBL2001918 | 0.74 | PKM (0.44) | HTR6PKMPKLRHTTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1996681 | 0.72 | PKM (0.41) | HTR6PKMPKLRHTTSMN1; SMN2 | |
| SCHEMBL1995457 | 0.71 | PKM (0.37) | HTR6PKMPKLRHTR2C | |
| SCHEMBL1998227 | 0.69 | HTR6 (0.36) | HTR6PKMPKLRHTR2C | |
| SCHEMBL1992945 | 0.69 | HTR6 (0.37) | HTR6PKMPKLRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885PKM 1287/4885PKLR 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.